Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Artesun (artesunate) is rapidly metabolized into an active metabolite DHA which contains an endoperoxide bridge that is activated by heme iron leading to oxidative stress, inhibition of protein and nucleic acid synthesis, which decreases parasite growth ...
Product Name : Artesun
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Details : OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Product Name : OT-101
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three time...
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pulmoheal™/ Artiveda™ Is Clinically Active Against Mild and Moderate Covid-19
Details : PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects w...
Product Name : PulmoHeal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19
Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Product Name : OT-101
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Manus Bio Awarded Additional Funding To Support Its Artemisinin Development Program
Details : Manus Bio has received a third funding award from the Bill & Melinda Gates Foundation to accelerate the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Artemisinin,Boswellia Serata,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta
Details : The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : $3.7 million
December 22, 2020
Lead Product(s) : Artemisinin,Boswellia Serata,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients...
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 20, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Funding
Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries
Details : Mateon Therapeutics announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Funding